Status:
RECRUITING
UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
Lead Sponsor:
AstraZeneca
Conditions:
Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
Eligibility:
All Genders
18+ years
Brief Summary
This is an ambispective, observational, multicenter and multicohort study, targeting patients with NSCLC initiating approved drugs developed by AZ or as part of an AZ alliance, in the participating co...
Eligibility Criteria
Inclusion
- Adult patients (≥ 18 years old)
- Patients with histologically or cytologically proven NSCLC
- Patients initiated with approved drugs developed by AZ or as part of an AZ alliance at the time of the enrollment or within the previous three weeks.
- Informed patients who consent to participate in the study as per local regulations.
Exclusion
- Patients participating in an interventional clinical trial for NSCLC\*
- \* with the exception on low-interventional studies (RIPH2) where the intervention does not involve the NSCLC treatment
- Patients already enrolled in another module of the cohort in UMBREALUNG
- Patients under safeguard of justice, curatorship or guardianship
Key Trial Info
Start Date :
December 16 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2032
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06726720
Start Date
December 16 2024
End Date
June 30 2032
Last Update
January 21 2026
Active Locations (40)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Aix-en-Provence, France
2
Research Site
Angers, France
3
Research Site
Aurillac, France
4
Research Site
Auxerre, France